




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tuszynski, Mark H.
Title: METHODS FOR THERAPY OF
NEURODEGENERATIVE
DISEASE OF THE BRAIN
Appl. No.: 09/620,174
Filing Date: 07/19/2000
Examiner: Chen, Shin-Lin
Art Unit: 1632

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below. <u>Michelle Sympson</u> (Printed Name)  (Signature) <u>April 7, 2003</u> (Date of Deposit)

DECLARATION OF MARK H. TUSZYNSKI, M.D.

I, Dr. Mark H. Tuszynski, declare as follows:

1. I am a Professor of Neurosciences and Director of the Center for Neural Repair at the University of California, San Diego (UCSD). I practice medicine as an attending neurologist at the UCSD and VA Medical Centers in La Jolla, California, and as the lead neurologist in ongoing clinical trials for treatment of Alzheimer's Disease (AD) using gene therapy in humans. I am also an inventor of the invention claimed in this US Patent Application Serial No. 09/060,543 (methods for *in vivo* gene therapy of neurodegenerative conditions), and in U.S. Patent No. 6,167,888 (claiming methods for *ex vivo* gene therapy of neurodegenerative conditions).

Background

2. The *in vivo* gene therapy method which is the subject of the present patent application has been tested in non-human primates and rodents, in preparation for human clinical studies to begin later this year. The *ex vivo* method which is the subject of the '888 patent is already being used in clinical trials, for treatment of AD.

Considered
derogated
8/31/05